0
0

Chapter 18. Monoamine Oxidase Inhibitors

K. Ranga Krishnan, M.D.
DOI: 10.1176/appi.books.9781585623860.411849

Sections

Excerpt

Monoamine oxidase inhibitors (MAOIs) were first identified as effective antidepressants in the late 1950s. An early report suggested that iproniazid, an antitubercular agent, had mood-elevating properties in patients who had been treated for tuberculosis (Bloch et al. 1954). Following these observations, two studies confirmed that iproniazid did indeed have antidepressant properties (Crane 1957; Kline 1958). Zeller (1963) reported that iproniazid caused potent inhibition of monoamine oxidase (MAO) enzymes both in vivo and in vitro in the brain. He also reported that the medication reversed some of the actions of reserpine. Because reserpine produced significant depression as a side effect, it was suggested that iproniazid might have mood-elevating properties.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
TABLE 18–1. Classification of monoamine oxidase inhibitor (MAOI) drugs by structure, selectivity, and reversibility
Table Reference Number
TABLE 18–2. Indications for use of monoamine oxidase inhibitors (MAOIs)
Table Reference Number
TABLE 18–3. Food restrictions for monoamine oxidase inhibitors (MAOIs)
Table Reference Number
TABLE 18–4. Drug interactions with monoamine oxidase inhibitors (MAOIs)

References

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
 
Amrein R, Allen SR, Guentert TW, et al: Pharmacology of reversible MAOIs. Br J Psychiatry 144:66–71, 1989
 
Amrein R, Guntert TW, Dingemanse J, et al: Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology (Berl) 106 (suppl):S24–S31, 1992
 
Amsterdam JD: A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64:208–214, 2003
[PubMed]
 
Amsterdam JD, Bodkin JA: Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 26:579–586, 2006
[PubMed]
 
Baker GB, Urichuk LJ, McKenna KF, et al: Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 19:411–426, 1999
[PubMed]
 
Blackwell B, Marley E, Price J, et al: Hypertensive interactions between monoamine oxidase inhibitors and food stuffs. Br J Psychiatry 113:349–365, 1967
[PubMed]
 
Bloch RG, Doonief AS, Buchberg AS, et al: The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann Intern Med 40:881–900, 1954
[PubMed]
 
Cesura AM, Pletscher A: The new generation of monoamine oxidase inhibitors. Prog Drug Res 38:171–297, 1992
[PubMed]
 
Cheese and tranylcypromine (letter). BMJ 3(5718):354, 1970
 
Cooper AJ: MAO inhibitors and headache (letter). BMJ 2:420, 1967
 
Crane GE: Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatry Research Reports 8:142–152, 1957
[PubMed]
 
Cronin D: Monoamine-oxidase inhibitors and cheese (letter). BMJ 5469:1065, 1965
 
Cusson JR, Goldenberg E, Larochelle P: Effect of a novel monoamine oxidase inhibitor, moclobemide, on the sensitivity to intravenous tyramine and norepinephrine in humans. J Clin Pharmacol 31:462–467, 1991
[PubMed]
 
DaPrada M, Kettler R, Burkard W, et al: Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines/tyramine pressor effects in rats, in Monoamine Oxidase and Disease. Edited by Tipton K, Dostert P, Strolin Benedetti M. New York, Academic Press, 1984, pp 137–154
 
DaPrada M, Kettler R, Keller HH, et al: Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248: 400–414, 1989
 
Davidson J, Turnbull C: Loss of appetite and weight associated with the monoamine oxidase inhibitor isocarboxazid. J Clin Psychopharmacol 2:263–266, 1982
[PubMed]
 
Davidson J, Raft D, Pelton S: An outpatient evaluation of phenelzine and imipramine. J Clin Psychiatry 48:143–146, 1987a
 
Davidson J, Walker JI, Kilts C: A pilot study of phenelzine in the treatment of post-traumatic stress disorder. Br J Psychiatry 150:252–255, 1987b
 
Evans DL, Davidson J, Raft D: Early and late side effects of phenelzine. J Clin Psychopharmacol 2:208–210, 1982
[PubMed]
 
Feiger AD, Rickels K, Rynn MA, et al: Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 67:1354–1361, 2006
[PubMed]
 
Finberg JPM, Youdim MBH: Reversible monoamine oxidase inhibitors and the cheese effect, in Monoamine Oxidase and Disease: Prospects for Therapy With Reversible Inhibitors. Edited by Tipton KF, Dostert P, Strolin Benedetti M. New York, Academic Press, 1984, pp 479–485
 
Gabelic I, Kuhn B: Moclobemide (Ro 11–1163) versus tranylcypromine in the treatment of endogenous depression (abstract). Acta Psychiatr Scand Suppl 360:63, 1990
[PubMed]
 
Gerlach M, Youdim MB, Riederer P: Pharmacology of selegiline. Neurology 47 (6, suppl 3):S137–S145, 1996
 
Glick R, Harrison W, Endicott J, et al: Treatment of premenstrual dysphoric symptoms in depressed women. J Am Med Womens Assoc 46:182–185, 1991
[PubMed]
 
Goldstein DM, Goldberg RL: Monoamine oxidase inhibitor-induced speech blockage (case report). J Clin Psychiatry 47:604, 1986
[PubMed]
 
Goodheart RS, Dunne JW, Edis RH: Phenelzine associated peripheral neuropathy: clinical and electrophysiologic findings. Aust N Z J Med 21:339–340, 1991
[PubMed]
 
Haefely W, Burkard WP, Cesura AM, et al: Biochemistry and pharmacology of moclobemide: a prototype RIMA. Psychopharmacology (Berl) 106 (suppl):S6–S15, 1992
 
Hagan JJ, Middlemiss DN, Sharpe PC, et al: Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol Sci 18:156–163, 1997
[PubMed]
 
Harrison WM, Stewart J, Ehrhardt AA, et al: A controlled study of the effects of antidepressants on sexual function. Psychopharmacol Bull 21:85–88, 1985
[PubMed]
 
Hedberg DL, Gordon MW, Glueck BC Jr: Six cases of hypertensive crisis in patients on tranylcypromine after eating chicken livers. Am J Psychiatry 122:933–937, 1966
[PubMed]
 
Himmelhoch JM, Fuchs CZ, Symons BJ: A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 170:628–634, 1982
[PubMed]
 
Himmelhoch JM, Thase ME, Mallinger AG, et al: Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148:910–916, 1991
[PubMed]
 
Husain M, Edmondson DE, Singer TP: Kinetic studies on the catalytic mechanism of liver monoamine oxidase. Biochemistry 21:595–600, 1982
[PubMed]
 
Jacobson JN: Anorgasmia caused by an MAOI (letter). Am J Psychiatry 144:527, 1987
[PubMed]
 
Jenike MA: Rapid response of severe obsessive-compulsive disorder to tranylcypromine. Am J Psychiatry 138:1249–1250, 1981
[PubMed]
 
Johnstone EC: Relationship between acetylator status and response to phenelzine. Mod Probl Pharmacopsychiatry 10:30–37, 1975
[PubMed]
 
Johnstone EC, Marsh W: The relationship between response to phenelzine and acetylator status in depressed patients. Proc R Soc Lond B Biol Sci 66:947–949, 1973
[PubMed]
 
Kelly D, Mitchell-Heggs N, Sherman D: Anxiety and the effects of sodium lactate assessed clinically and physiologically. Br J Psychiatry 119:129–141, 1971
[PubMed]
 
Kennedy SH, Warsh JJ, Mainprize E, et al: A trial of isocarboxazid in the treatment of bulimia. J Clin Psychopharmacol 8:391–396, 1988
[PubMed]
 
Kline NS: Clinical experience with iproniazid (Marsilid). J Clin Exp Psychopathol 19 (suppl 1):72–78, 1958
 
Kosten TR, Frank JB, Dan E, et al: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 179:366–370, 1991
[PubMed]
 
Larsen JK, Gjerris A, Holm P, et al: Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. Acta Psychiatr Scand 84:564–570, 1991
[PubMed]
 
Lawlor BA, Aisen PS, Green C, et al: Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Geriatr Psychiatry 12:319–322, 1997
[PubMed]
 
Liebowitz MR, Schneier F, Campeas R, et al: Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 49:290–300, 1992
[PubMed]
 
Lydiard RB, Laraia MT, Howell EF, et al: Phenelzine treatment of panic disorder: lack of effect on pyridoxal phosphate levels. J Clin Psychopharmacol 9:428–431, 1989
[PubMed]
 
Lyytinen J, Kaakkola S, Ahtila S, et al: Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease. Mov Disord 12:497–505, 1997
[PubMed]
 
Mahmood I: Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 33:91–102, 1997
[PubMed]
 
McElroy SL, Keck PE Jr, Pope HG Jr, et al: Pharmacological treatment of kleptomania and bulimia nervosa. J Clin Psychopharmacol 9:358–360, 1989
[PubMed]
 
McGrath PJ, Stewart JW, Harrison W, et al: Phenelzine treatment of melancholia. J Clin Psychiatry 47:420–422, 1986
[PubMed]
 
McGrath PJ, Stewart JW, Fava M, et al: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163:1531–1541, 2006
[PubMed]
 
Mendelson G: Narcotics and monoamine oxidase-inhibitors (letter). Med J Aust 1:400, 1979
[PubMed]
 
Murphy DL, Garrick NA, Aulakh CS, et al: New contribution from basic science of understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psychiatry 45:37–43, 1984
[PubMed]
 
Murphy DL, Sunderland T, Garrick NA, et al: Selective amine oxidase inhibitors: basic to clinical studies and back, in Clinical Pharmacology in Psychiatry. Edited by Dahl SG, Gram A, Potter W. Berlin, Springer Verlag, 1987, pp 135–146
 
O'Brien S, McKeon P, O'Regan M, et al: Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 12:104–109, 1992
[PubMed]
 
Paykel ES, West PS, Rowan PR, et al: Influence of acetylator phenotype on antidepressant effects of phenelzine. Br J Psychiatry 141:243–248, 1982
[PubMed]
 
Pearce LB, Roth JA: Human brain monoamine oxidase type B: mechanism of deamination as probed by steady-state methods. Biochemistry 24:1821–1826, 1985
[PubMed]
 
Quitkin F, Rifkin A, Klein DF: Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Arch Gen Psychiatry 36:749–760, 1979
[PubMed]
 
Quitkin FM, Liebowitz MR, Stewart JW, et al: l-Deprenyl in atypical depressives. Arch Gen Psychiatry 41:777–781, 1984
[PubMed]
 
Quitkin FM, McGrath PJ, Stewart JW, et al: Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 47:935–941, 1990
[PubMed]
 
Quitkin FM, Harrison W, Stewart JW, et al: Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 48:319–323, 1991
[PubMed]
 
Ramsay RR, Singer TP: The kinetic mechanisms of monoamine oxidases A and B. Biochem Soc Trans 19:219–223, 1991
[PubMed]
 
Rossel L, Moll E: Moclobemide versus tranylcypromine in the treatment of depression. Acta Psychiatr Scand Suppl 360:61–62, 1990
[PubMed]
 
Rowan PR, Paykel ES, West PS, et al: Effects of phenelzine and acetylator phenotype. Neuropharmacology 20(12B):1353–1354, 1981
 
Simpson GM, Gratz SS: Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther 52:286–291, 1992
[PubMed]
 
Stack CG, Rogers P, Linter SPK: Monoamine oxidase inhibitors and anaesthesia: a review. Br J Anaesth 60:222–227, 1988
[PubMed]
 
Thase ME, Mallinger AG, McKnight D, et al: Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 149:195–198, 1992
[PubMed]
 
Tyrer PJ, Candy J, Kelly D: A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 32:237–254, 1973
[PubMed]
 
Vallejo J, Gasto C, Catalan R, et al: Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry 151:639–642, 1987
[PubMed]
 
Versiani M, Mundim FD, Nardi AE, et al: Tranylcypromine in social phobia. J Clin Psychopharmacol 8:279–283, 1988
[PubMed]
 
Versiani M, Nardi AE, Mundim FD, et al: Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353–360, 1992
[PubMed]
 
Walsh BT, Stewart JW, Roose SP, et al: A double-blind trial of phenelzine in bulimia. J Psychiatr Res 19:485–489, 1985
[PubMed]
 
Walsh BT, Gladis M, Roose SP, et al: A controlled trial of phenelzine in bulimia. Psychopharmacol Bull 23:49–51, 1987
[PubMed]
 
Wells DG: MAOI revisited. Can J Anaesth 36:64–74, 1989
[PubMed]
 
Wesnes KA, Simpson PM, Christmas L, et al: Acute cognitive effects of moclobemide and trazodone, alone and in combination with alcohol, in the elderly. Br J Clin Pharmacol 27:647P–648P, 1989
 
White K, Razani J, Cadow B, et al: Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial. Psychopharmacology (Berl) 82:258–262, 1984
[PubMed]
 
Youdim MBH, DaPrada M, Amrein R (eds): The cheese effect and new reversible MAO-A inhibitors. Proceedings of the Round Table of the International Conference on New Directions in Affective Disorders, Jerusalem, Israel, April 5–9, 1987
 
Zajecka J, Fawcett J: Susceptibility to spontaneous MAOI hypertensive episodes (letter). J Clin Psychiatry 52:513–514, 1991
[PubMed]
 
Zeller EA: Diamine oxidase, in The Enzymes, 2nd Edition, Vol 8. Edited by Boyer PD, Lardy H, Myrback K. London, Academic Press, 1963, pp 313–335
 
Zisook S: Side effects of isocarboxazid. J Clin Psychiatry 45 (7, part 2):53–58, 1984
 
Zisook S, Braff DL, Click MA: Monoamine oxidase inhibitors in the treatment of atypical depression. J Clin Psychopharmacol 5:131–137, 1985
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Which of the following is an irreversible inhibitor of monoamine oxidase B (MAO-B)?
2.
Which of the following monoamine oxidase inhibitors (MAOIs) is a nonhydrazine irreversible MAOI that is chemically similar to amphetamine?
3.
Both single- and double-blind studies have found that the classic monoamine oxidase inhibitors (MAOIs) are effective in treating which of the following disorders?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 23.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 47.  >
What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 18.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation